Immutep Limited (ASX:IMM)
Australia · Delayed Price · Currency is AUD | Market Cap | 36.84M -90.2% |
| Revenue (ttm) | 19.93M +295.2% |
| Net Income | -79.30M |
| EPS | -0.05 |
| Shares Out | 1.47B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,036,939 |
| Open | 0.0230 |
| Previous Close | 0.0240 |
| Day's Range | 0.0230 - 0.0270 |
| 52-Week Range | 0.0200 - 0.4700 |
| Beta | 2.32 |
| Analysts | Buy |
| Price Target | 0.11 (+353.2%) |
| Est. Earnings | Feb 21, 2027 |
About Immutep
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb... [Read more]
Financial Performance
In fiscal year 2026, Immutep's revenue was 19.93 million, an increase of 295.22% compared to the previous year's 5.04 million. Losses were -79.30 million, 29.1% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IMM stock is "Buy." The 12-month stock price target is $0.11, which is an increase of 353.20% from the latest price.
News
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced th...
Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and clinicopatholo...
Immutep Limited - Depositary Receipt Price Target Increased by 19.55% to $80.11
The average one-year price target for Immutep Limited - Depositary Receipt (NASDAQGM:IMMP) has been revised to $80.11 / share. This represents an increase of 19.55% from the prior estimate of $67.01 d...
Immutep announces data from its Phase I study of IMP761
Immutep (IMMP) announced positive data from its Phase I study of IMP761 from a late-breaking abstract at ACR Convergence 2026 in Orlando, Florida. ACR Convergence is the annual scientific meeting…
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune disea...
Immutep Limited Receives A$2.16 million French R&D Tax Incentive
Immutep Limited announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) research tax incentive...
Immutep Receives A$2.16 Mln French Tax Incentive To Support Drug Development
(RTTNews) - Immutep Ltd. (IMMP), a clinical-stage immunotherapy company, said Wednesday it received cash payment of €1.36 million, approximately A$2.16 million, under the French government's research ...
Immutep Earnings release: Q1 2027
Immutep released its Q1 2027 earnings on October 27, 2026, summarizing the period's financial results.
Immutep presents HRQoL data from EFTISARC-NEO trial
Immutep (IMMP) announced health-related quality of life, or HRQoL, data from the investigator-initiated EFTISARC-NEO Phase II trial. The data are being presented in an ePoster at the European Society ...
Immutep, Monash University secure further ARC linkage projects
Immutep (IMMP) announced that the Australian Research Council, or ARC, has awarded Monash University a grant of A$652,248 over three years under the ARC’s Linkage Projects scheme to support its…
Immutep regains compliance with Nasdaq minimum bid price requirement
Immutep (IMMP) announced that it has received written notification from the Listing Qualifications Department of Nasdaq confirming that the company has regained compliance with the minimum bid price r...
Immutep receives A$856,669 cash rebate from Australia R&D tax incentive program
Immutep (IMMP) announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred o...
Immutep Receives ~A$0.86 Million R&D Tax Incentive
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases...
Immutep Ltd trading halted, news pending
19:50 EDT Immutep (IMMP) Ltd trading halted, news pending
Immutep provides update on development strategy for eftilagimod alfa
Immutep (IMMP) provided an update on its development strategy for eftilagimod alfa. Following the early discontinuation of the TACTI-004 study, Immutep has been conducting a detailed root cause analys...
Immutep Annual report: H2 2026
Immutep has published its H2 2026 annual report on August 30, 2026.
Immutep Annual report: H2 2026
Immutep has published its H2 2026 annual report on August 30, 2026.
Immutep Slides: Corporate presentation
Immutep has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2026.
Immutep granted new patent for eftilagimod alfa combination
Immutep (IMMP) announced the grant of a new patent entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office, or USPTO. This…
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a ...
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) an...
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advise...
IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of th...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP). Such investors are...